BerandaATAI • NASDAQ
add
ATAI Life Sciences NV
$2,25
Setelah Jam Perdagangan Normal:(0,44%)+0,0100
$2,26
Tutup: 26 Jun, 18.29.10 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$2,20
Rentang hari
$2,17 - $2,25
Rentang tahun
$1,03 - $2,64
Kapitalisasi pasar
451,69 jt USD
Volume Rata-Rata
2,89 jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,56 jt | — |
Biaya operasional | 9,99 jt | -8,84% |
Laba bersih | -26,43 jt | 1,06% |
Margin laba bersih | -1,70 rb | — |
Penghasilan per saham | -0,15 | 11,76% |
EBITDA | -19,05 jt | 13,79% |
Tarif pajak efektif | -0,49% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 98,20 jt | -7,57% |
Total aset | 195,78 jt | -27,25% |
Total liabilitas | 43,51 jt | -5,13% |
Total ekuitas | 152,27 jt | — |
Saham yang beredar | 200,34 jt | — |
Harga terhadap nilai buku | 2,89 | — |
Tingkat pengembalian aset | -27,13% | — |
Tingkat pengembalian modal | -29,67% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -26,43 jt | 1,06% |
Kas dari operasi | -17,84 jt | 20,96% |
Kas dari investasi | -11,01 jt | -196,02% |
Kas dari pembiayaan | 59,60 jt | — |
Perubahan kas bersih | 30,78 jt | 375,65% |
Arus kas bebas | -11,27 jt | 38,58% |
Tentang
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Didirikan
2018
Situs
Karyawan
54
